ArticleNature communications2026
The transcription factor C/EBPβ promotes hyperglycemia-elicited glycolysis and liver cancer progression.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Hyperglycemia and its related diseases, such as diabetes, dramatically accelerate cancer progression. However, the underlying mechanisms remain poorly understood, and the development of anticancer therapies based on them has largely stalled. Transcription factor CCAAT/enhancer binding protein beta (C/EBPβ) is strongly associated with glucose metabolic disorders and cancer progression. Here we show that C/EBPβ is significantly upregulated in hepatocellular carcinoma patients previously diagnosed with diabetes. Notably, high glucose activates C/EBPβ transcription via ROS-dependent PERK-eIF2α-ATF4 signaling. Intriguingly, the LAP isoforms of C/EBPβ, but not the LIP isoform, upregulate key glycolytic effectors (GLUT1 and LDHA) and the oncoprotein HRAS, thereby promoting glycolysis and proliferation in liver cancer cells. Remarkably, hyperglycemia-accelerated hepatocellular glycometabolism and hepatocellular carcinoma progression in male mice are greatly prevented by hepatocyte-specific C/EBPβ deletion or Lucicebtide (ST101) treatment, a clinical phase-II C/EBPβ inhibitory peptide. Moreover, human C/EBPβ isoform LAP1 mimics the effect of hyperglycemia to boost hepatocellular glycometabolism and accelerate hepatocellular carcinoma progression. Thus, C/EBPβ is a critical regulator and potential therapeutic target for glucose-fueled cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.